Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1G2032R and ALKG1202R
AbstractClinical treatment by FDA-approved ROS1/ALK inhibitor Crizotinib significantly improved the therapeutic outcomes. However, the emergence of drug resistance, especially driven by acquired mutations, have become an inevitable problem and worsened the clinical effects of Crizotinib. To combat d...
Main Authors: | Siming Liu, Chuan Huang, Chunhui Huang, Yaqi Huang, Yonghuan Yu, Guowu Wu, Fengqiu Guo, Ying Jiang, Shanhe Wan, Zhengguang Zhu, Yuanxin Tian, Jianghua Zhu, Jiajie Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/14756366.2023.2227779 |
Similar Items
-
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy
by: Balázs Jóri, et al.
Published: (2022-09-01) -
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer
by: Giulio Metro, et al.
Published: (2023-11-01) -
miR-1202 acts as anti-oncomiR in myeloid leukaemia by down-modulating GATA-1S expression
by: Raffaele Sessa, et al.
Published: (2024-02-01) -
R-lipoic acid overdosing affects platelet life span via ROS mediated autophagy
by: Jing Liu, et al.
Published: (2018-10-01) -
Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation
by: Wang H, et al.
Published: (2018-05-01)